GPT and metabolic syndrome: After adjusting for all covariables in model 1 plus clinical and laboratory parameter confounders, including SBP, DBP, a diabetes diagnosis, lymphocytes, basophils, RBC, MPV, FSG, albumin, uric acid, and ALT, participants in Q3 and Q4 groups had a higher dyslipidemia odds in model 2 (ORQ3 vs. Q1 = 1.20, 95% CI: 1.01–1.42, ORQ4 vs. Q1 = 1.31, 95% CI: 1.10–1.56).